Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Iterative Health Reports Expanded Trial Performance Data at Digestive Disease Week 2026, Demonstrating Consistent Outperformance of Industry Benchmarks at Double the Scale